An Isolated Activin-Binding Actriia Polypeptide Comprising the Seq Id No: 7 and Uses for Promoting Bone Growth
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 12 of these applications claim priority to application 60/739,462, filed Nov 23, 2005. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 7,951,771 | Activin-Actriia Antagonists and Uses for Promoting Bone Growth In force · Medium confidence UsedRemaining | Acceleron Pharma Inc. | In force | Medium confidence | ||
| US 8,067,360 | A Method for Promoting Bone Growth Using Activin-Actriia Antagonists In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | ||
| US 8,128,933 | A Method of Promoting Bone Growth by an Anti-Activin B Antibody In force · High confidence | Acceleron Pharma, Inc. | In force | High confidence | ||
| US 8,486,403 | A Method of Promoting Bone Growth by an Anti-Activin a Antibody In force · High confidence | Acceleron Pharma, Inc. | In force | High confidence | ||
| US 8,629,109 | Method for Promoting Bone Growth Using Activin-Actriia Antagonists In force · Low confidence | Acceleron Pharma Inc. | In force | Low confidence | ||
| US 9,163,075 | AN ISOLATED POLYNUCLEOTIDE THAT ENCODES AN ActRIIa-Fc FUSION POLYPEPTIDE In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | ||
| US 9,480,742 | Method of Promoting Bone Growth by an Anti-Actriia Antibody In force · High confidence | Acceleron Pharma, Inc. | In force | High confidence | ||
| US 9,572,865 | Activin-Actriia Antagonists and Uses for Treating Multiple Myeloma In force · High confidence | Acceleron Pharma, Inc. | In force | High confidence | ||
| US 10,071,135 | A Method of Identifying an Agent That Promotes Bone Growth or Increases Bone Density In force · Medium confidence | Acceleron Pharma Inc. | In force | Medium confidence | ||
| US 10,239,940 | Method of Promoting Bone Growth by an Anti-Actriia Antibody In force · High confidence | Acceleron Pharma Inc. | In force | High confidence | ||
| 10 more records in this group · Pro | ||||||
10 of 20 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 20, including 12 expiring within the 18 months from Nov 19, 2026.
13 of these are in force and held by Acceleron Pharma Inc..
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.